1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 25,200 | 27,200 | 24.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.06. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | 5 | HKEx | ||
| 26.06. | DUALITYBIO-B (09606): (1) CHANGE OF JOINT COMPANY SECRETARY, AUTHORIZED REPRESENTATIVE AND PROCESS AGENT; (2) WAIVER FROM STRICT COMPLIANCE WITH RULES ... | 5 | HKEx | ||
| 26.06. | DUALITYBIO-B (09606): GRANT OF RESTRICTED SHARE UNITS UNDER THE 2025 SHARE SCHEME | 1 | HKEx | ||
| 26.06. | DUALITYBIO-B (09606): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026 | 1 | HKEx | ||
| 12.06. | DUALITYBIO-B (09606): ACCEPTANCE BY THE SHANGHAI STOCK EXCHANGE OF APPLICATION MATERIALS FOR THE RMB SHARE ISSUE | 2 | HKEx | ||
| 10.06. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 10.06. | DUALITYBIO-B (09606): VOLUNTARY ANNOUNCEMENT - ACCEPTANCE ON COUNSELLING FROM SHANGHAI SECURITIES REGULATORY BUREAU REGARDING PROPOSED LISTING OF RMB ... | 1 | HKEx | ||
| 04.06. | DUALITYBIO-B (09606): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON JUNE 26, 2026 | 1 | HKEx | ||
| DUALITY BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.06. | DUALITYBIO-B (09606): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 04.06. | DUALITYBIO-B (09606): (1) PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE SHARES; (2) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES (INCLUDING ... | - | HKEx | ||
| 03.06. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 26.05. | DUALITYBIO-B (09606): NEXT DAY DISCLOSURE RETURN | 3 | HKEx | ||
| 19.05. | DUALITYBIO-B (09606): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE PLAN UNDER THE REPURCHASE MANDATE AND PROPOSED INCREASE IN SHAREHOLDING BY CHAIRMAN OF ... | 3 | HKEx | ||
| 13.05. | DUALITYBIO-B (09606): INSIDE INFORMATION NOTICE OF EXERCISE OF THE DB-1311/BNT324 COST & PROFIT/LOSS SHARING OPTION | 2 | HKEx | ||
| 29.04. | DUALITYBIO-B (09606): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON APRIL 29, 2026 | 2 | HKEx | ||
| 14.04. | DUALITYBIO-B (09606): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON APRIL 29, 2026 | 3 | HKEx | ||
| 14.04. | DUALITYBIO-B (09606): NOTICE OF THE EXTRAORDINARY GENERAL MEETING | 3 | HKEx | ||
| 14.04. | DUALITYBIO-B (09606): (1) PROPOSED ISSUE OF RMB SHARES UNDER SPECIFIC MANDATE AND LISTING ON THE SCI-TECH BOARD AND OTHER ANCILLARY RESOLUTION; (2) PROPOSED ... | 1 | HKEx | ||
| 13.04. | DUALITYBIO-B (09606): (1) PROPOSED ISSUE OF RMB SHARES UNDER SPECIFIC MANDATE AND LISTING ON THE SCI-TECH BOARD; AND (2) PROPOSED AMENDMENTS TO THE ARTICLES ... | 5 | HKEx | ||
| 11.04. | BioNTech SE: BioNTechs und DualityBios Antikörper-Wirkstoff-Konjugat-Kandidat Trastuzumab Pamirtecan zeigte klinisch relevante Wirksamkeit bei Patientinnen mit rezidivierendem HER2-exprimierendem Gebärmutterkrebs | 2.277 | GlobeNewswire (Deutschland) | Trastuzumab Pamirtecan, ein innovativer gegen HER2 gerichteter Antikörper-Wirkstoff-Konjugat-Kandidat, erreichte den primären Wirksamkeitsendpunkt in einer Phase-2-Kohorte bei stark vorbehandelten Patientinnen... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,00 | -1,68 % | BioNTech-Aktie: Klagen verschärfen die Milliardenkrise | BioNTech sieht sich neuen Patentklagen von Arbutus Biopharma und Genevant Sciences zur Lipid-Nanopartikel-Technologie seines COVID-19-Impfstoffs gegenüber. Gleichzeitig ist der Umsatz von 17,3 Milliarden... ► Artikel lesen | |
| MODERNA | 47,620 | +0,18 % | Moderna: A Stock to Watch or a Risky Bet? | ||
| PALATIN TECHNOLOGIES | 7,610 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,222 | 0,00 % | Defence Therapeutics Inc.: Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform | Montreal, Quebec--(Newsfile Corp. - July 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| QIAGEN | 36,335 | -0,66 % | AKTIEN IM FOKUS 2: Danaher enttäuscht Anleger - Auch Sartorius-Kurs leidet | (neu: Kurse mit Danaher im offiziellen Handel, Analystenstimmen) FRANKFURT/NEW YORK (dpa-AFX) - Der Quartalsbericht von Danaher hat im Diagnostikbereich am Dienstag international eine Welle der Enttäuschung... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 13,680 | +0,15 % | Summit Therapeutics Flags Going Concern Risk Over Cash Needs | ||
| TARSUS PHARMACEUTICALS | 58,66 | 0,00 % | Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89 | ||
| PRAXIS PRECISION MEDICINES | 324,95 | -0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,430 | -0,04 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,26 | -0,01 % | Apogee Therapeutics Aktie erreicht Rekordhoch von 134,34 USD | ||
| DISC MEDICINE | 74,12 | 0,00 % | Disc Medicine Inc: Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria | Aligned with the FDA that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response and could potentially support a traditional approvalOn track for expected CRL response submission... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 52,95 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,740 | -0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ERASCA | 19,110 | 0,00 % | Erasca, Inc.: Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | At RDE of 32 mg QD, encouraging monotherapy responses with 57% uORR in 2L+ KRAS G12X pancreatic cancer in U.S. trial and median relative dose intensity of 100% Monotherapy has been generally well-tolerated... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 8,690 | 0,00 % | Vir Biotechnology: Abgang des Finanzchefs schickt Aktie auf Talfahrt |
DUALITY BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +7,69 % bei einem Aktienkurs von 25,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DUALITY BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.